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I have also been part of a team which 
has initiated an awareness campaign, with a 
zero-dollar budget, aimed solely at educating 
the public about the importance of using 
antibiotics wisely, and being aware of the 
threat superbugs pose. 
The beauty of our campaign is that we 
use data generated from our epidemiological 
research in the Gulf that are published in 
high-tier journals, and translate this into 
everyday language for people. Our campaign 
has interested more health activists, who 
have volunteered to produce multimedia 
materials that help clarify the complicated 
science behind antimicrobial resistance.
We were grateful to see that the Saudi 
Food and Drug Authority launched a 
follow-up campaign last November to raise 
awareness about antibiotics. We feel our 
work is impacting, and may have triggered 
an organisational move towards raising 
antibiotic awareness.
Combating antimicrobial resistance 
should not be done at an individual level. It 
should be carried out as a global mission on 
multiple collaborative, innovative and social 
levels. We hope our slow and gentle moves 
are concrete in contributing to the important 
fight against superbugs. 
More details about superbug research 
are available from uqccr.uq.edu.au and 
superbugs.imb.uq.edu.au. To contribute 
to the University’s superbug research, 
visit uq.edu.au/giving or email the 
Pro-Vice-Chancellor (Advancement) at   
pvca@uq.edu.au.
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global level. The pillars for this plan include 
initiating global surveillance on antimicrobial 
resistance, developing rapid diagnostic 
tools for early detection to allow early 
treatment of antibiotic-resistant bacteria, and 
conducting educational programs to limit the 
inappropriate use of antibiotics.
At the UQ Centre for Clinical Research, 
under the guidance of world-renowned 
Infectious Diseases expert, Professor David 
Paterson, and in partnership with other 
international organisations, we have initiated 
the first network of collaborating hospitals 
to monitor the emergence and spread of 
superbugs in the Gulf States. This research 
complements superbugs research by 
researchers at the Institute for Molecular 
Bioscience’s Centre for Superbug Solutions.
In the Arabian Peninsula, international 
expatriates are contributing heavily to the 
economic boom, and making more money 
than 50 per cent of the total population. The 
region is also home to the two holy mosques 
of Mecca and Medina for Muslims around 
the world. These factors are contributing to 
heavy travel activities, and travel is known to 
impact the international spread of infectious 
diseases. Antibiotic-resistant bacteria favours 
free intercontinental rides. Thus, studying 
antibiotic resistance in the Gulf region 
exemplifies the global spread of the problem. 
Planning the study and conducting the 
research were challenging. Coordinating 
a multinational study required many late 
nights and early morning phone calls, firing 
off unlimited emails, and flying hundreds of 
thousands of miles to attend meetings. 
We started with a dream that only 
became a reality through perseverance, 
dedication and teamwork; access to readily 
available, and well-equipped, research 
facilities; and a healthy dose of good luck. 
Despite still being in the early stages of our 
work, our published data is considered by 
many local and international experts to be 
landmark research in the area of antibiotic 
resistance in the Gulf States.
Our data has raised awareness about 
the issue of antimicrobial resistance in the 
region. I recently returned from overseas 
after attending high-level committee planning 
sessions for a strategic plan to combat 
antimicrobial resistance in the Gulf States. It 
was evident our produced data has made 
such an impact.
Having a rapid point-of-care diagnostic 
test that can identify antibiotic-resistant 
bacteria in minutes for a very low cost is 
indeed still ambitious, at this stage. Yet, 
biotechnology innovation is at the frontier 
with the level of advancements achieved in 
this era. 
We have started by exploring 
technologies, with an aim to advance 
monitoring the spread of antibiotic-resistant 
bacteria and hopefully produce results in a 
shorter turnaround time to help clinicians 
apply targeted therapy. 
Last June, the UK Government, with 
Nesta Foundation, announced the next 
Longitude Prize will be devoted to rapid, 
cheap, point-of-care diagnostics for 
antibiotic-resistant bacteria. The White 
House also announced a similar award last 
September.
As clinical microbiologists, we recognised 
the need for rapid diagnosis long before 
these announcements, and have taken a 
few steps towards that direction. In fact, a 
few days before the announcement of the 
Longitude Prize, I was awarded the Rolex 
Award for Enterprise as a Young Laureate 
to support our work for rapid diagnosis 
research and development.
As suggested by WHO, education is a 
pillar in the combat strategy for antimicrobial 
resistance. In some parts of the world, 
including where I am originally from, 
antibiotics can be sold over the counter 
without prescriptions, despite the existing 
banning law. It is clear that public education 
is needed in this regard.
For many decades, modern medicine has enjoyed the privilege of antibiotics, which have saved millions of lives 
all over the world. The discovery 
of antibiotics was intended to end 
the threat of infectious diseases. 
While they have helped humanity 
to control many fatal infections of 
the past — such as sore throat and 
puerperal fever — unfortunately the 
privilege of antibiotics is coming 
to an end. This is mainly due to 
antimicrobial resistance.
Antimicrobial resistance is 
a global issue that is not only 
endangering humanity, but also 
animal health. Our sophisticated 
surgeries and anticancer therapies 
are at risk. We are confronting bacteria 
that can be resistant to multiple antibiotics, 
including last-line treatments, making them 
nearly impossible to treat.
An economical review of antimicrobial 
resistance estimated that in 2050, 
antimicrobial resistance would kill 10 million 
more people — more than how many are 
anticipated to die from cancer.  In the United 
States alone, there are currently more 
than two million reported cases related 
to antimicrobial resistance, resulting in 23 
thousand deaths, and $20 billion in direct 
costs.
As a counter plan, the World Health 
Organization (WHO) set a strategic plan 
to combat antimicrobial resistance on a 
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